Wockhardt Limited - Product Pipeline Review - 2012

Wockhardt Limited – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Wockhardt Limited - Product Pipeline Review - 2012” provides data on the Wockhardt Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Wockhardt Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Wockhardt Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Wockhardt Limited - Brief Wockhardt Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Wockhardt Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Wockhardt Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Wockhardt Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Wockhardt Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Wockhardt Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Wockhardt Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Wockhardt Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Wockhardt Limited and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Wockhardt Limited; Wockhardt Limited - Key Therapeutics; Wockhardt Limited - Pipeline Overview and Promising Molecules; Wockhardt Limited - News; Wockhardt Limited - Latest Updates; Wockhardt Limited - Pipeline; Wockhardt Limited - Discontinued/Dormant Projects

List of Tables
List of Figures
Wockhardt Limited Snapshot
Wockhardt Limited Overview
Key Information
Key Facts
Wockhardt Limited – Research and Development Overview
Key Therapeutic Areas
Wockhardt Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Wockhardt Limited – Pipeline Products Glance
Wockhardt Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Wockhardt Limited – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Wockhardt Limited – Drug Profiles
Second Generation Ketolides
Product Description
Mechanism of Action
R&D Progress
Second Generation Oxas
Product Description
Mechanism of Action
R&D Progress
sTU-199
Product Description
Mechanism of Action
R&D Progress
WCK 2349
Product Description
Mechanism of Action
R&D Progress
WCK 4086
Product Description
Mechanism of Action
R&D Progress
WCK 4873
Product Description
Mechanism of Action
R&D Progress
WCK 771
Product Description
Mechanism of Action
R&D Progress
Wockhardt Limited – Pipeline Analysis
Wockhardt Limited – Pipeline Products by Therapeutic Class
Wockhardt Limited – Pipeline Products By Target
Wockhardt Limited – Pipeline Products by Route of Administration
Wockhardt Limited – Pipeline Products By Mechanism of Action
Wockhardt Limited - Dormant Projects
Wockhardt Limited – Company Statement
Wockhardt Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Wockhardt Limited, Recent Developments
Wockhardt Limited- Press Release
Apr 24, 2012: Wockhardt Launches Authorized Generic Of Parkinson’s Drug Stalevo With 180-Days Exclusivity
Jan 10, 2012: Wockhardt Launches Generic Version Of Rhinitis Drug Flonase Nasal Spray
Nov 18, 2009: Wockhardt launches anti-hypertensive drug Nicardipine injections in USA
Oct 14, 2009: Wockhardt Receives Final Approval From The US FDA For Risperidone
Oct 01, 2009: Wockhardt receives tentative USFDA nod for Alfuzosin tablets
Sep 29, 2009: Wockhardt gets final USFDA nod for Timolol Maleate.
Sep 29, 2009: Wockhardt Receives FDA Approval For Tamsulosin Capsules
Sep 29, 2009: Wockhardt Receives FDA Approval For Tamsulosin Capsules For Treatment Of Benign Prostatic Hyperplasia
Feb 26, 2009: Wockhardt to launch generic version of ulcer drug Ranitidine syrup in the US market
Feb 26, 2009: Wockhardt To Launch Ranitidine Syrup For Treatment Of Ulcers And Hyperacidity In US
Feb 17, 2009: Wockhardt To Launch Generic Version Of Migraine Drug Sumatriptan In US Market
Feb 12, 2009: Wockhardt To Launch Leveiracetam For Treatment Of Epilepsy In US
Feb 12, 2009: Wockhardt to launch Leveiracetam, a generic version of epilepsy drug in the US market
Feb 11, 2009: Wockhardt gets USFDA nod for Sumatriptan Succinate
Feb 11, 2009: Wockhardt To Launch Divalproex ER For Treatment Of Epilepsy In US
Feb 11, 2009: Wockhardt to launch Divalproex ER in the US market.
Financial Deals Landscape
Wockhardt Limited, Deals Summary
Wockhardt Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Sheffield Bio-Science Enters Into Collaboration With Wockhardt
Wockhardt Forms Joint Venture With Representaciones E Investigaciones Medicas
Wockhardt Forms Joint Venture With Pharma Dynamics
Licensing Agreements
Wockhardt Enters Into In-licensing Agreement With DSM Nutritional Products
Wockhardt Enters Into Licensing Agreement With Sinclair Pharma
Wockhardt Enters Into Licensing Agreement With Crawford Healthcare
Wockhardt Enters Into Licensing Agreement With Gnosis
Wockhardt Enters Into An Agreement With SYRIO PHARMA
Wockhardt Enters Into Licensing Agreement With Advanced Biotechnologies
Wockhardt Signs An In-licensing Agreement With Crawford Healthcare
Wockhardt Enters Into Agreement With Life Sciences Investments For Vitix
Debt Offering
Wockhardt Completes Private Placement Of Foreign Currency Convertible Bonds For $110 Million
Asset Transactions
Danone To Acquire Nutrition Business Of Wockhardt
Bristol Labs Acquires Luton Plant From Wockhardt
Acquisition
Genopharm Acquires Girex And Mazal From Wockhardt
Wockhardt Completes Sale Of esparma To Mova
Wockhardt Acquires Morton Grove Pharma
Wockhardt Acquires Negma Labs
Wockhardt Acquires Pinewood Labs
Wockhardt Acquires Dumex India From Royal Numico
Wockhardt Acquires esparma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Wockhardt Limited, Key Information
Wockhardt Limited, Key Facts
Wockhardt Limited – Pipeline by Indication, 2012
Wockhardt Limited – Pipeline by Stage of Development, 2012
Wockhardt Limited – Monotherapy Products in Pipeline, 2012
Wockhardt Limited – Phase II, 2012
Wockhardt Limited – Phase I, 2012
Wockhardt Limited – Pre-Clinical, 2012
Wockhardt Limited – Pipeline By Therapeutic Class, 2012
Wockhardt Limited - Pipeline By Target, 2012
Wockhardt Limited – Pipeline By Route of Administration, 2012
Wockhardt Limited – Pipeline Products By Mechanism of Action, 2012
Wockhardt Limited - Dormant Developmental Projects,2012
Wockhardt Limited, Other Locations
Wockhardt Limited, Subsidiaries
Wockhardt Limited, Deals Summary
Sheffield Bio-Science Enters Into Collaboration With Wockhardt
Wockhardt Forms Joint Venture With Representaciones E Investigaciones Medicas
Wockhardt Forms Joint Venture With Pharma Dynamics
Wockhardt Enters Into In-licensing Agreement With DSM Nutritional Products
Wockhardt Enters Into Licensing Agreement With Sinclair Pharma
Wockhardt Enters Into Licensing Agreement With Crawford Healthcare
Wockhardt Enters Into Licensing Agreement With Gnosis
Wockhardt Enters Into An Agreement With SYRIO PHARMA
Wockhardt Enters Into Licensing Agreement With Advanced Biotechnologies
Wockhardt Signs An In-licensing Agreement With Crawford Healthcare
Wockhardt Enters Into Agreement With Life Sciences Investments For Vitix
Wockhardt Completes Private Placement Of Foreign Currency Convertible Bonds For $110 Million
Danone To Acquire Nutrition Business Of Wockhardt
Bristol Labs Acquires Luton Plant From Wockhardt
Genopharm Acquires Girex And Mazal From Wockhardt
Wockhardt Completes Sale Of esparma To Mova
Wockhardt Acquires Morton Grove Pharma
Wockhardt Acquires Negma Labs
Wockhardt Acquires Pinewood Labs
Wockhardt Acquires Dumex India From Royal Numico
Wockhardt Acquires esparma

List of Figures
Wockhardt Limited – Pipeline by Indication, 2012
Wockhardt Limited – Pipeline by Stage of Development, 2012
Wockhardt Limited – Monotherapy Products in Pipeline, 2012
Wockhardt Limited – Pipeline By Therapeutic Class, 2012
Wockhardt Limited – Pipeline By Route of Administration, 2012
Wockhardt Limited - Pipeline Products By Mechanism of Action, 2012

Order Online - visit http://www.researchandmarkets.com/reports/2141818

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.